Citations

Showing 10 of 108036 citations.

How Cool It Is: Targeted Temperature Management for Brain Protection Post–Cardiac Arrest
Rabinstein, Alejandro A.

Mayo Clinic

Seminars in Respiratory and Critical Care Medicine | January 28, 2016 | Volume: 37 | Issue: 01 | Pages: 034-041

10.1055/s-0035-1570357 | PMID 26820272 Get It

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease
Heyer, Christina M., Sundsbak, Jamie L., Chapman, Arlene B., Torres, Vicente E. , Grantham, Jared J. , Bae, Kyongtae T., Schrier, Robert W., Braun, William E. , Steinman, Theodore I., Mrug, Michal , Brosnahan, Godela , Irazabal, María V. , Flessner, Michael F., Moore, Charity G., Landsittel, Douglas , Harris, Peter C. , Investigators, for the HALT PKD and CRISP, Patterson, Charity G. , Hopp, Katharina , Abebe, Kaleab Z , Perrone, Ronald D. , Yu, Alan S.L. , Bennett, William M. , Investigators, for the HALT PKD and CRISP, Harris, Peter C , Torres, Vicente E , Irazabal, Maria V

Mayo Clinic

Journal of the American Society of Nephrology | January 28, 2016 | Volume: 27 | Issue: 9 | Pages: 2872-2884

10.1681/asn.2015050583 | PMID 26823553 Get It

Autosomal dominant polycystic kidney disease (ADPKD) often results in ESRD but with a highly variable course. Mutations to PKD1 or PKD2 cause ADPKD; both loci have high levels of allelic heterogeneity. We evaluated genotype-phenotype correlations in 1119 patients (945 families) from the HALT Progression of PKD Study and the Consortium of Radiologic Imaging Study of PKD Study. The population was defined as: 77.7% PKD1, 14.7% PKD2, and 7.6% with no mutation detected (NMD). Phenotypic end points were sex, eGFR, height–adjusted total kidney volume (htTKV), and liver cyst volume. Analysis of the eGFR and htTKV measures showed that the PKD1 group had more severe disease than the PKD2 group, whereas the NMD group had a PKD2-like phenotype. In both the PKD1 and PKD2 populations, men had more severe renal disease, but women had larger liver cyst volumes. Compared with nontruncating PKD1 mutations, truncating PKD1 mutations associated with lower eGFR, but the mutation groups were not differentiated by htTKV. PKD1 nontruncating mutations were evaluated for conservation and chemical change and subdivided into strong (mutation strength group 2 [MSG2]) and weak (MSG3) mutation groups. Analysis of eGFR and htTKV measures showed that patients with MSG3 but not MSG2 mutations had significantly milder disease than patients with truncating cases (MSG1), an association especially evident in extreme decile populations. Overall, we have quantified the contribution of genic and PKD1 allelic effects and sex to the ADPKD phenotype. Intrafamilial correlation analysis showed that other factors shared by families influence htTKV, with these additional genetic/environmental factors significantly affecting the ADPKD phenotype.
GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Baumgart, Sandra, Chen, Nai-Ming, Zhang, Jin‐San , Billadeau, Daniel D. , Gaisina, Irina N. , Kozikowski, Alan P. , Singh, Shiv K. , Fink, Daniel , Klindt, Caroline , Bamlet, William R. , Köenig, Alexander , Heßmann, Elisabeth , Gress, Thomas M. , Ellenrieder, Volker , Neeße, Albrecht , Ströbel, Philipp , Zhang, Lizhi , Bamlet, William R , Singh, Shiv K

Mayo Clinic

Molecular Cancer Therapeutics | January 28, 2016 | Volume: 15 | Issue: 3 | Pages: 491-502

10.1158/1535-7163.mct-15-0309 | PMID 26823495 Get It

Abstract We aimed to investigate the mechanistic, functional, and therapeutic role of glycogen synthase kinase 3β (GSK-3β) in the regulation and activation of the proinflammatory oncogenic transcription factor nuclear factor of activated T cells (NFATc2) in pancreatic cancer. IHC, qPCR, immunoblotting, immunofluorescence microscopy, and proliferation assays were used to analyze mouse and human tissues and cell lines. Protein–protein interactions and promoter regulation were analyzed by coimmunoprecipitation, DNA pulldown, reporter, and ChIP assays. Preclinical assays were performed using a variety of pancreatic cancer cells lines, xenografts, and a genetically engineered mouse model (GEMM). GSK-3β–dependent SP2 phosphorylation mediates NFATc2 protein stability in the nucleus of pancreatic cancer cells stimulating pancreatic cancer growth. In addition to protein stabilization, GSK-3β also maintains NFATc2 activation through a distinct mechanism involving stabilization of NFATc2–STAT3 complexes independent of SP2 phosphorylation. For NFATc2–STAT3 complex formation, GSK-3β–mediated phosphorylation of STAT3 at Y705 is required to stimulate euchromatin formation of NFAT target promoters, such as cyclin-dependent kinase-6, which promotes tumor growth. Finally, preclinical experiments suggest that targeting the NFATc2–STAT3–GSK-3β module inhibits proliferation and tumor growth and interferes with inflammation-induced pancreatic cancer progression in KrasG12D mice. In conclusion, we describe a novel mechanism by which GSK-3β fine-tunes NFATc2 and STAT3 transcriptional networks to integrate upstream signaling events that govern pancreatic cancer progression and growth. Furthermore, the therapeutic potential of GSK-3β is demonstrated for the first time in a relevant Kras and inflammation-induced GEMM for pancreatic cancer. Mol Cancer Ther; 15(3); 491–502. ©2016 AACR.
Spinal arteriovenous fistulae in patients with hereditary hemorrhagic telangiectasia: A case report and systematic review of the literature
Brinjikji, Waleed , Nasr, Deena M. , Cloft, Harry J. , Iyer, Vivek , Lanzino, Giuseppe

Mayo Clinic

Interventional Neuroradiology | January 28, 2016 | Volume: 22 | Issue: 3 | Pages: 354-361

10.1177/1591019915623560 | PMID 26823330 Get It

Background Although rare, spinal arteriovenous malformations (AVMs) are thought to be more prevalent in the hereditary Hereditary Hemorrhagic Telangiectasia (HHT) population. Methods We report a case of a spinal AVM in a 37-year-old female with HHT treated with endovascular embolization. In addition, we report findings from a systematic review of the literature on the clinical characteristics, angioarchitecture, and clinical outcomes of HHT patients with spinal AVMs. Results The patient is a 37 year-old female with definite HHT who presented with a one-year history of progressive gait difficulty. The spinal fistula was incidentally detected on chest computed tomography (CT). Spinal angiography demonstrated a large perimedullary arteriovenous fistula was supplied by a posterolateral spinal artery. The fistula was treated with detachable coils. The patient made a complete neurological recovery. Our systematic review yielded 25 additional cases of spinal AVMs in HHT patients. All fistulae were perimedullary (100.0%). Treatments were described in 24 of the 26 lesions. Endovascular-only treatment was performed in 16 cases (66.6%) and surgical-only treatment was performed in five cases (20.8%). Complete or near-complete occlusion rates were 86.7% (13/15) for endovascular treated cases, 100.0% (4/4) for surgery and 66.6% (2/3) for combined treatments. Overall, 80.0% of patients (16/20) reported improvement in function following treatment, 100.0% (5/5) in the surgery group and 84.6% (11/13) reported improvement in the endovascular group. Conclusions Spinal fistulae in HHT patients are usually type IV perimedullary fistulae. Both endovascular and surgical treatments appeared to be effective in treating these lesions. However, it is clear that endovascular therapy has become the preferred treatment modality.
Can endosheath technology open primary care doors to Barrett’s esophagus screening by transnasal endoscopy?
Iyer, Prasad G. , Chak, Amitabh

Mayo Clinic

Endoscopy | January 28, 2016 | Volume: 48 | Issue: 02 | Pages: 105-106

10.1055/s-0034-1393561 | PMID 26820077 Get It

Balance between Hyperinflammation and Immunosuppression in Sepsis
Yadav, Hemang , Cartin‐Ceba, Rodrigo

Mayo Clinic

Seminars in Respiratory and Critical Care Medicine | January 28, 2016 | Volume: 37 | Issue: 01 | Pages: 042-050

10.1055/s-0035-1570356 | PMID 26820273 Get It

Anesthesia Care Capacity at Health Facilities in 22 Low‐ and Middle‐Income Countries
Hadler, Rachel A. , Chawla, Sagar , Stewart, Barclay T. , McCunn, Maureen, Kushner, Adam L.

Mayo Clinic

World Journal of Surgery | January 28, 2016 | Volume: 40 | Issue: 5 | Pages: 1025-1033

10.1007/s00268-016-3430-4 | PMID 26822158 Get It

AbstractBackgroundGlobally, an estimated 2 billion people lack access to surgical and anesthesia care. We sought to pool results of anesthesia care capacity assessments in low‐ and middle‐income countries (LMICs) to identify patterns of deficits and provide useful targets for advocacy and intervention.MethodsA systematic review of PubMed, Cochrane Database of Systematic Reviews, and Google Scholar identified reports that documented anesthesia care capacity from LMICs. When multiple assessments from one country were identified, only the study with the most facilities assessed was included. Patterns of availability or deficit were described.ResultsWe identified 22 LMICs (15 low‐ and 8 middle‐income countries) with anesthesia care capacity assessments (614 facilities assessed). Anesthesia care resources were often unavailable, including relatively low‐cost ones (e.g., oxygen and airway supplies). Capacity varied markedly between and within countries, regardless of the national income. The availability of fundamental resources for safe anesthesia, such as airway supplies and functional pulse oximeters, was often not reported (72 and 36 % of hospitals assessed, respectively). Anesthesia machines and the capability to perform general anesthesia were unavailable in 43 % (132/307 hospitals) and 56 % (202/361) of hospitals, respectively.ConclusionWe identified a pattern of critical deficiencies in anesthesia care capacity in LMICs, including some low‐cost, high‐value added resources. The global health community should advocate for improvements in anesthesia care capacity and the potential benefits of doing so to health system planners. In addition, better quality data on anesthesia care capacity can improve advocacy, as well as the monitoring and evaluation of changes over time and the impact of capacity improvement interventions.
Answer to February 2016 Photo Quiz
Ramanan, Poornima , Wengenack, Nancy L. , Pritt, Bobbi S. , Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | January 28, 2016 | Volume: 54 | Issue: 2 | Pages: 510-510

10.1128/jcm.00376-14 Get It

Photo Quiz: A 54-Year-Old Male with Acute Myelogenous Leukemia Presenting with Right Periorbital Swelling and Diplopia
Ramanan, Poornima , Wengenack, Nancy L. , Pritt, Bobbi S. , Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | January 28, 2016 | Volume: 54 | Issue: 2 | Pages: 249-249

10.1128/jcm.00375-14 | PMID 26822766 Get It

Dual-Energy CT for Evaluation of Intra- and Extracapsular Silicone Implant Rupture
Glazebrook, Katrina N. , Jacobson, Steven R., McCollough, Cynthia M., Leng, Shuai

Mayo Clinic

Case Reports in Radiology | January 28, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-4

10.1155/2016/6323709 | PMID 26942031 Get It

Silicone implants are commonly used for both breast augmentation and breast reconstruction. With aging of the implant, the silicone envelope may become weak or may rupture. The technique of choice for evaluation of implant integrity is breast MRI; however this may be contraindicated in some patients or the cost may be prohibitive. Dual-energy CT allows determination of density and atomic number of tissue and can provide material composition information. We present a case of extracapsular implant rupture with MRI and dual-energy CT imaging and surgical correlation.